Anatomy hub
Elbow: Options and What the Evidence Actually Shows
Lateral and medial epicondylitis (tennis/golfer's elbow) dominate elbow regenerative searches. Most cases resolve with load management — injectates are adjuncts.
Anatomy and clinical context
The common extensor and flexor origins at the epicondyles are overload injuries. Tendinopathy, not acute inflammation, is the modern framing.
Eccentric loading and activity modification cure many cases. Injections and surgery are reserved for refractory symptoms.
Illustration of the elbow joint
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Load management, eccentric exercise, bracing, and time.
- Step 2
Injections
Corticosteroid (short-term), PRP, and other orthobiologics in refractory cases.
- Step 3
Surgery
Open or arthroscopic debridement for persistent failure of nonoperative care.
Where cell therapy fits
PRP literature in epicondylitis is mixed but more mature than many MSC same-day claims. Banking is optional context, not the primary pitch for this anatomy.
- Most epicondylitis improves without surgery or cell therapy.
- PRP is more commonly discussed here than culture-expanded MSC products.
- If you are already banking for other joints, your cells remain available for future physician-directed use.
Selected citations
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.